Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

The share market may be struggling to get into gear on Thursday but that isn't stopping one ASX All Ords stock from racing higher.

In morning trade, its shares are up a massive 58% to 76 cents thanks to some big news.

A man has a surprised and relieved expression on his face.

Image source: Getty Images

Which ASX All Ords stock is rocketing?

The stock in question is Dimerix Ltd (ASX: DXB), which is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases.

This morning, investors have been scrambling to buy its shares after it entered into an exclusive U.S. licensing agreement with Amicus Therapeutics (NASDAQ: FOLD) for the commercialisation of its Phase 3 drug candidate DMX-200.

DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal Phase 3 study, ACTION3, for the treatment of Focal Segmental Glomerulosclerosis (FSGS) kidney disease.

In early 2024, the ASX All Ords stock reported positive interim results from the ACTION3 trial in FSGS. It showed that DMX-200 was performing better than placebo in reducing proteinuria with no safety concerns to date. Full enrolment of ACTION3 is expected by year-end 2025.

Big money deal

According to the release, the deal will see Amicus Therapeutics gain exclusive rights to commercialise DMX-200 for all indications in the United States, while Dimerix retains the rights in other global markets.

As part of the agreement, the ASX All Ords stock will receive the following:

  • US$30 million (~A$48 million) upfront.
  • Up to US$75 million (~A$199 million) in milestone payments tied to Phase 3 trial success and regulatory approval.
  • US$35 million (A$56 million) on first commercial sale in the U.S.
  • Up to US$410 million (A$653 million) in commercial milestone payments.
  • Tiered royalties on net sales in the U.S. ranging from low-teens to low-twenties.
  • Up to US$40 million (A$64 million) for future indication milestones

Commenting on the news, the ASX All Ords stock's CEO and managing director, Dr Nina Webster, said:

We are delighted to partner with Amicus in the United States. The Amicus team has a remarkable history of successfully delivering rare disease medicines to those in need. Their expertise and resources will be crucial to help achieve our mutual objective of commercializing this innovative treatment.

I'm grateful to the dedicated Dimerix team, trial participants, and investigators for their continued commitment to developing a new therapy for patients with FSGS who currently have a poor prognosis and very limited treatment options.

Following today's gain, the Dimerix share price is now up almost 140% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »